HC Wainwright reissued their buy rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report released on Wednesday morning.

Other equities analysts have also issued research reports about the stock. Wells Fargo & Company reaffirmed a buy rating and set a $51.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Bank of America reaffirmed a buy rating and set a $36.00 price target (up previously from $34.00) on shares of Ascendis Pharma A/S in a research report on Monday, September 25th. Credit Suisse Group reaffirmed an outperform rating and set a $50.00 price target (up previously from $30.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Wedbush reaffirmed an outperform rating and set a $10.71 price target (down previously from $65.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Finally, Leerink Swann reaffirmed a hold rating and set a $28.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $36.45.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) traded up $0.21 on Wednesday, hitting $37.39. 98,400 shares of the company traded hands, compared to its average volume of 112,475. Ascendis Pharma A/S has a fifty-two week low of $19.21 and a fifty-two week high of $42.00.

Institutional investors have recently added to or reduced their stakes in the company. RA Capital Management LLC increased its position in shares of Ascendis Pharma A/S by 3.2% in the second quarter. RA Capital Management LLC now owns 5,580,690 shares of the biotechnology company’s stock worth $154,920,000 after acquiring an additional 170,700 shares in the last quarter. California Public Employees Retirement System acquired a new stake in Ascendis Pharma A/S during the 2nd quarter valued at $430,000. VHCP Management II LLC grew its holdings in Ascendis Pharma A/S by 21.6% during the 2nd quarter. VHCP Management II LLC now owns 986,492 shares of the biotechnology company’s stock valued at $27,385,000 after purchasing an additional 175,000 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Ascendis Pharma A/S during the 2nd quarter valued at $15,403,000. Finally, Trexquant Investment LP acquired a new stake in Ascendis Pharma A/S during the 2nd quarter valued at $244,000. 78.93% of the stock is owned by institutional investors.

WARNING: “Ascendis Pharma A/S’s (ASND) Buy Rating Reaffirmed at HC Wainwright” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/12/14/ascendis-pharma-ass-asnd-buy-rating-reaffirmed-at-hc-wainwright.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.